GSAJumpPage

Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Peripheral T cell Lymphoma
Natural History Study of Children and Adults with Chordoma
A Phase 1/2, Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination with Pembrolizumab (KEYTRUDA) with Relapsed or Refractory Solid Tumors
A Phase 1/2, Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination with Pembrolizumab (KEYTRUDA) with Relapsed or Refractory Solid Tumors
A Phase II Pilot Study of Avelumab in Combination with Hypofractionated Radiotherapy in Patients with Relapsed Refractory Multiple Myeloma
A Phase 1 Study of Interleukin-15 in Combination with Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
A Phase I Study of Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Local-Regionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase II Study of Neoadjuvant Androgen Deprivation Therapy Combined with Enzalutamide and Abiraterone Using Multiparametric MRI and 18F-DCFPyL-PET/CT in Newly Diagnosed Prostate Cancer
A Phase 2 Trial of The MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.
Long term follow-up of mesothelioma patients and their family members with germline mutations in BAP1 and other genes
A Phase I study of Moxetumomab pasudotox (Lumoxiti™) and Rituximab (Rituxan®) for Relapsed Hairy Cell Leukemia
Natural History Study of Men at High Genetic Risk for Prostate Cancer
Perioperative MVT-5873, a fully human monoclonal antibody against a CA 19-9 epitope, for operable CA 19-9 producing pancreatic cancers, cholangiocarcinomas, and metastatic colorectal cancers
An open-label, first-in-human, multi-center study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of a thorium-227 labeled antibody-chelator conjugate, BAY 2287411 Injection, in patients with solid tumors known to express
Phase II Study of Nivolumab (anti-PD1), Tadalafil and Oral Vancomycin in Patients with Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer from Colorectal or Pancreatic Cancers
A Phase 2 Study of Response-Adapted Therapy with Copanlisib and Rituximab in Untreated Follicular Lymphoma #xD;
Tissue Acquisition and Genomics Analysis of Breast and Other Gynecologic Malignancies
A Phase II Study of Olaparib in Patients with Metastatic/Advanced Urothelial Carcinoma with DNA-Repair Defects
Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
A Natural History Study of Children and Adults with Fibrolamellar Hepatocellular Carcinoma
A Randomized Phase 2 Trial of Durvalumab (MEDI4736) with or without SBRT in Clinical Stage I, II, and IIIA Non-Small Cell Lung Cancer (NSCLC)
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Natural History and Biospecimen Accrual Study for Children and Adults with Rare Solid Tumors
Phase II Clinical Trial of Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma
Phase II trial evaluating Nivolumab in patients with IDH-mutant gliomas with and without hypermutator phenotype
A Phase II Study of M7824 in Subjects with Recurrent Respiratory Papillomatosis
Phase 1 with Expansion Cohorts in a Study of NEO-201 In Adults with Chemo-resistant Solid Tumors
A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior
Exploring Outcomes and Risk in Patients with Rare Central Nervous System Tumors
An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma.
Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
Phase II Study of the Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
Phase II Study Evaluating Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects with Hereditary Diffuse Gastric Cancer Syndrome
Phase II clinical trial of sunitinib in sarcomas of the central nervous system
PRISM: A Platform protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)
A Phase I Clinical Trial of T cells expressing a novel fully-human anti-BCMA CAR for treating multiple myeloma
An intermediate access protocol for selumetinib for treatment of neurofibromatosis type 1 with inoperable, progressive/symptomatic plexiform neurofibromas
A Phase 1/2 open-label, multi-center, safety and tolerability study of a single dose of 68Ga-PSMA-R2 in patients with biochemical relapse (BR) and metastatic prostate cancer (mPCa).
Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers
A Phase I/II Trial in Patients with Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in which the Gene Encoding CISH was Inactivated Using the CRISPR/Cas9 System
Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults with Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (cNF)
Phase II Study of Olaparib in Subjects with Malignant Mesothelioma
A Single Arm Pilot Study Combining CRLX101, a Nanoparticle Camptothecin, with Enzalutamide in Patients with Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
Pilot Study of Medication Adherence in Children, Adolescents, and Adults with Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials
Individual Patient Expanded Access Use of CV301 for the Treatment of Triple Positive Metastatic Breast Cancer
A Bioequivalence Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer
Feasibility and Preliminary Efficacy of an Enhanced Mindfulness Intervention for Children with High Grade Brain Tumors and Their Caregivers.
A Phase I/II study of immunotherapy combination BN-Brachyury vaccine, M7824, ALT-803 and Epacadostat (QuEST1)
Bicalutamide with or without metformin for biochemical recurrence in prostate cancer patients (BIMET-1)
A Phase I/II Trial to Evaluate the Safety and Immunogenicity of a Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
Treatment of Patients with Castration Resistant Prostate Cancer using a Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors#xD;
A Phase I Study of the Mesothelin-Targeted Immunotoxin LMB-100 in Combination with SEL-110 in Subjects with Malignant Mesothelioma
An open-label Phase 1 trial to evaluate the safety and tolerability of a Modified Vaccinia Ankara (MVA) priming followed by fowlpox booster vaccines modified to express brachyury and T cell costimulatory molecules (MVA-BN-Brachyury/FPV-Brachyury)
A Phase IB/II Single-arm Study of M7824 (MSB0011359C) in Combination with Gemcitabine in Adults with Previously Treated Advanced Adenocarcinoma of the Pancreas
A Pilot Study to Evaluate the Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men with Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Phase II Trial of M7824 in Subjects with HPV Associated Malignancies
A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients with Metastatic Cancer
Generation of Cancer Antigen-Specific T-Cells from Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential Future Therapy
Long Term Follow-up of Subjects Exposed to NY-ESO-1c259 T, a Genetically Engineered NY-ESO-1 Specific T Cell Receptor
A Phase 2 Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
Phase I Trial Using a Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
A Phase I Trial of Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy with Floxuridine and Dexamethasone in Combination with Systemic Chemotherapy for Patients with Colorectal Cancer Metastatic to the Liver
Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer
Phase I Trial of 5-aza-4'-thio-2'-deoxycytidine (Aza-TdC) in Patients with Advanced Solid Tumors
Phase III randomized Adjuvant study of MK-3475 (pembrolizumab) in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) versus Observation
Phase II Trial of Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
Molecular Characterization of Viral-associated Tumors, Tumors occurring in the Setting of HIV or other Immune Disorders and Castleman Disease
CC-4047-BRN-001: A Phase 2 Clinical Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults with Recurrent or Progressive Primary Brain Tumors
A Phase II Trial to Evaluate the Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
Phase Ib multi-indication study of anetumab ravtansine (BAY 94-9343) in patients with mesothelin expressing advanced or recurrent malignancies
Phase IIB Study of Cediranib and Olaparib Combination in Women with Recurrent Platinum Resistant Epithelial Ovarian Cancer, Fallopian Tubal and/or Primary Peritoneal Cancer without Germline BRCA Mutation, Who Had Prior Bevacizumab (D8488C0001) #xD;
A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma
A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicinium (oportuzumab monatox, VB4-845) in Subjects with High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated with BCG
A Feasibility Study of Mobile Sensor Technologies to Assess General Symptomology of Cancer Patients
A Phase 1/2 Proof-of-Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects with Relapsed/Refractory B-cell Malignancies
Phase I Trial of image guided focally dose escalated prostate SBRT for locally recurrent prostate cancer after prior radiotherapy
Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and other Extranodal Diffuse Large B-cell Lymphomas#xD;
Assessing the Impact of Glioblastoma Multiforme on the Quality of Life of Patients and Caregivers (The GlioQoL Observational Study)
A Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer harboring KRAS G12R Mutations
Phase I/II Evaluation of the Immune Checkpoint Inhibitor, Pembrolizumab in Combination with Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, or Unresectable Locally Advanced or Metastatic Non-small Cell Lung Cancer
Leukapheresis for CAR-Therapy Manufacturing
Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy
A Phase 2 Single-arm Study to Evaluate Safety and Efficacy of CRS-207 with Pembrolizumab in Adults with Previously-Treated Malignant Pleural Mesothelioma
Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas
Phase 1b Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of PEN-866 in Advanced Solid Malignancies
A Phase I Study of Immunotherapy with E6 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions
Phase I/II Study of T-DM1 alone versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*1101 Patients
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
Prospective Study of Clonal Evolution in Follicular Lymphoma
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS Cancers
Collection of Malignant Ascites, Pleural Fluid and Blood from Patients with Solid Tumors
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal Cancer
Evaluation of 18F-DCFPyL PSMA- versus 18F-NaF-PET imaging for Detection of Metastatic Prostate Cancer
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
A Phase II Trial of the DNA Methyl Transferase Inhibitor, SGI-110 (Guadecitabine), in Children and Adults with Wild Type GIST, Pheochromocytoma and Paraganglioma Associated with Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
A Phase 1, Open-label, Dose Escalation Study of MGA271 in Pediatric Patients with B7-H3-Expressing Relapsed or Refractory Solid Tumors
An Open-label Phase 2 Study to Evaluate PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
A Phase II Trial of the Mitogen Activated Protein Kinase Kinase (MEK1/2) inhibitor Selumetinib (AZD6244 hydrogen sulfate) in Patients with Neurofibromatosis Type 1 (NF1) related Gastrointestinal Stomal Tumors (GIST)
A Phase 2 Study of Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination with Capecitabine and Oxaliplatin (CAPOX) in Subjects with Advanced Biliary Tract Carcinoma (BTC)
Phase II Trial of Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer with Positive Peritoneal Cytology
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma after Progression on Platinum-Based Chemotherapy
Phase II Trial of Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
A Randomized Phase II trial of Standard of Care Alone or in Combination with Ad-CEA vaccine and Avelumab in Patients with Previously Untreated Metastatic or Unresectable Colorectal Cancer
Phase II Evaluation of Nivolumab, an Immune Checkpoint Inhibitor, alone or in combination with Oral Decitabine/Tetrahydrouridine as Second Line Therapy for Non-Small Cell Lung Cancer
A Phase I/II Trial of the Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination with the Src Family Kinase (SFK) Inhibitor Dasatinib in Patients with Embryonal and Alveolar Rhabdomyosarcoma
T Cells Expressing a Fully-human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-expressing Lymphomas
Prospective Evaluation and Molecular Profiling in Patients with Gastric Tumors
Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer
A Phase Ib Open Label, Dose Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination with M9241 (NHS-IL12) in Subjects with Locally Advanced, Unresectable, or Metastatic Solid Tumors
Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Clinical Sequencing of Cancer and Tissue Repository: ClinOmics
A randomized, double blind phase II trial of Surgery, Radiation Therapy plus Temozolomide and Pembrolizumab with and without HSPPC-96 in newly diagnosed Glioblastoma (GBM)
A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia
A Phase II Trial of CUDC-907 in Patients with Metastatic and Locally Advanced Thyroid Cancer
Long-Term Follow up of Patients Undergoing Hematopoietic Stem Cell Transplantation
A Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy Subjects with Non-Small Cell Lung Cancer
A Phase I Study of a Combination of MM-398 and Veliparib in solid tumors
Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) in Women with Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Phase I Trial of TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 plus Temozolomide versus Temozolomide alone in Adults with Recurrent Anaplastic Astrocytoma and Glioblastoma
A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human Interleukin IL-15 (rhIL-15) in Adults with Metastatic Cancers
Phase I/II Study of PROSTVAC in Combination with Nivolumab and / or Ipilimumab in Men with Prostate Cancer
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Phase I/II Study of Lenalidomide Combined with Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
A Phase II Study of Avelumab in Subjects with Recurrent Respiratory Papillomatosis
Phase I/II Evaluation of Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients with Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms with Pleuropulmonary Metastases
A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 with or without PD-1 Blockade for HPV-Associated Cancers
Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration
Evaluation of the Natural History of and Specimen Banking for Patients with Tumors of the Central Nervous System
Phase I Evaluation of Adjuvant Oral Decitabine and Tetrahydrouridine with or without Celecoxib in Patients Undergoing Pulmonary Metastasectomy
Phase II Trial with Safety Run-in of the Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma
Collection of Peripheral Blood Mononuclear Cells (PBMCs) from Healthy Subjects for the Expansion of T Cells for Adoptive Cell Therapy
A Pilot Study of Combined Immune Checkpoint Inhibition in combination with ablative therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a CD70-Binding Chimeric Antigen Receptor to Patients with CD70-Expressing Cancers
A Phase I/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
A Phase I Study of the Mesothelin-Targeted Immunotoxin LMB-100 with or without Nab-Paclitaxel (Abraxane) in Patients with Malignant Mesothelioma
A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
A Phase I/II Trial of CRLX101, a Nanoparticle Camptothecin with Olaparib in Patients with Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers
An Open Label Phase Ib Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Maximum Tolerated Dose of Anetumab Ravtansine in Combination with Pemetrexed 500 mg/m2 and Cisplatin 75 mg/m2 in Subjects with
Pilot Study of Ultrasound Guided Focal Thermal Ablation of Prostate Cancer
Phase II Evaluation of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients with Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
Phase 1 Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma
A Phase 1/2 study of baricitinib, a JAK1/2 inhibitor, in chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (SCT)
A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment with Osimertinib (AZD9291, Tagrisso)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal
An Open Label Phase 1B/2 Trial of TRC 105 and Sorafenib in Patients with Hepatocelluar Carcinoma (HCC)
A Phase I Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of a Vaccine-Based Immunotherapy Regimen (VBIR) for Prostate Cancer (PF-06753512)
A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer
Phase I Study of Pembrolizumab in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Biospecimen Procurement for Experimental Transplantation and Immunology Branch Immunotherapy Protocols
A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients with Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL)
A Phase 1b/2 study of AZD9668, an oral neutrophil elastase inhibitor, in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation
Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
Collection and Distribution of Blood Components from Healthy Donors for In Vitro Research Use
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Blood and Lymph Node Malignancy
Psychological Benefits of a Normalized Camping Experience for Children with Cancer
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer
Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients with Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence
Magnetic Resonance Imaging at 1.5 and 3.0 Tesla
Multidisciplinary Etiologic Study of Familial Testicular Cancer
Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study
Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni Syndrome
Eligibility Screening and Tissue Procurement for the NIH Intramural Research Program Clinical Protocols
Follow-up for Patients Previously Enrolled on the Center for Cancer Research Protocols
DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study
Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas
Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction
Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors
A Phase II Trial in Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, With Cross-Over at Disease Progression
A Phase I Study of Single-agent AZD1775 (MK-1775), a Wee1 Inhibitor, in Patients with Advanced Refractory Solid Tumors
A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma
Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors#xD; #xD;
A Phase I Trial of TRC102 (methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors and Lymphomas
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults with Refractory Solid Tumors, Lymphomas, or Myelodysplastic Syndromes
Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults with Refractory Solid Tumors#xD;
Molecular Analysis for Therapy Choice (MATCH) (EAY131)
A Pilot Study of an Integrated Imaging Strategy to Phenotype Progression of Liver Tumors during and after Chemoembolization
Biomarkers in Acute Graft-Versus-Host Disease (GVHD) and Extracorporeal Photopheresis added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD
T Cells Expressing a Fully-human Anti- CD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
A Phase 1 Trial of Pomalidomide in Combination with Liposomal Doxorubicin in Patients with Advanced or Refractory Kaposi Sarcoma
A Phase II Study using LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors during Treatment with Transarterial Embolization (TAE) Alone or combined with Thermal Ablation
Docetaxel and PROSTVAC for Metastatic Castration Sensitive Prostate Cancer
Follow-Up Evaluation for Gene-Therapy Related Delayed Adverse Events after Participation in Pediatric Oncology Branch Clinical Trials
A randomized, open-label, active-controlled, Phase II study of intravenous anetumab ravtansine (BAY 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin and progressed on first line
Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Treatment of Children with Cancer
Prostvac in Patients with Biochemically Recurrent Prostate Cancer
A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab
Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophelia Cohort (HGDS-3)
A Prospective Randomized and Phase II Trial for Metastatic Melanoma Using Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
A Phase 1 Study of bb2121 in BCMA-expressing Multiple Myeloma
An Open-Label, Phase 1 Study of the Safety and Immunogenicity of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Subjects with Non-Small Cell Lung Cancer
Gut Microbiota in Patients with HCC
A Phase II Randomized Trial of Lenalidomide (NSC # 703813, IND # 70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
A Phase I-II trial of Everolimus and Sorafenib in Patients with Recurrent High-Grade Gliomas
Pilot Study of Allogeneic/Syngeneic Blood Stem Cell Transplantation in Patients with High-Risk and Recurrent Pediatric Sarcomas
Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue
Phase II trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi- Center Trial
Randomized Control Trial of Adrenalectomy versus Observation for Subclinical Hypercortisolism
A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
A Phase II Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
A Phase I/II Trial ofCrolibulin (EPC2407) plus Cisplatin in Adults with Solid Tumors with a Focus on Anaplastic Thyroid Cancer (ATC)
Phase II Randomized, Placebo-Controlled Trial of PROSTVAC (PSA-TRICOM) in Patients with Clinically Localized Prostate Cancer Undergoing Active Surveillance
A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Cross-Over, Phase II.5 Study of Saracatinib (AZD0530), a Selective Src Kinase Inhibitor, in Patients with Recurrent Osteosarcoma Localized to the Lung
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals with Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs)
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination with Standard Chemotherapy in Patients with Advanced and/or Treatment-Refractory Solid
Phase II Study of Axitinib (AG-013736) with Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma
A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults with Refractory Solid Tumors
A Pilot Study of Metformin in Patients with a Diagnosis of Li-Fraumeni Syndrome
Electromagnetic Tracking of Devices During Interventional Procedures
A Comparison of Methods for Assisting Needle Angle Selection During Image-guided Tissue Biopsy
Prospective Randomized Trial Comparing Navigation with Xperguide vsElectromagnetic Tracking vsConventional Methods during Percutaneous Image Guided Procedures
Imaging Review of Patients who have Undergone Imaging Studies in the Radiology and Imaging Sciences Department of the NIH Clinical Center
Fusion Guided Thermal Ablation Combined with External Beam Radiation for Hepatic Neoplasms
Prospective Randomized Multicenter Trial Comparing Navigation with 3D Roadmap vsConventional Angiography During Trans-arterial Embolization
Prospective Pilot Observational Study Examining Cone Beam CT and CT Thermometry During Ablations
Sonalleve MR-HIFU for Palliation of Bone PainPilot Study
A Targeted Phase I/II trial of ZD6474 (Vandetanib; CAPRELSA) Plus the Proteasome Inhibitor, Bortezomib (Velcade®), in Adults with Solid Tumors with a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects with B-cell Malignancies
A Pilot Study of Tc-94m Sestamibi PET MDR Imaging
A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination with Trastuzumab in Breast Cancer Subjects with Brain Metastases
Phase II Trial of Depsipeptide (NSC 630176) in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-cell Lymphoma
A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients with Recurrent Brain Metastases#xD;
Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma
Collection of Blood, Fluid, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer or Normal Volunteers
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected
A Phase Ib, Dose Escalation, Multiple Dose Trial with HuMax-IL8 in Patients with Metastatic or Unresectable, Locally Advanced Malignant Solid Tumors
Phase I/II Trial of Yttrium-90-labeled Daclizumab (anti-CD25) Radioimmunotherapy with High-dose BEAM Chemotherapy and Autologous Hematopoietic Stem Cell Rescue in Recurrent and Refractory Hodgkin's Lymphoma
A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults with Refractory Solid Tumors
A Phase I Study of Cabozantinib plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors
A Phase 2, open-label, single-arm, intra-subject dose-escalation study to investigate the biological activity, safety, tolerability, and pharmacokinetics of ponesimod in subjects with symptomatic moderate or severe chronic GVHD inadequately responding to
Phase I/II Trial of Vandetanib in Combination with Metformin in Subjects with HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Phase 2 Study of Everolimus Therapy in Patients with Birt-Hogg-Dubé Syndrome (BHD)-Associated Kidney Cancer
Pilot Study of Allogeneic/Syngeneic Blood Stem Cell Transplantation in Patients with High-Risk and Recurrent Pediatric Sarcomas
A Phase I Trial of Pomalidomide for Children with Recurrent, Progressive or Refractory CNS Tumors
A Phase I/II Study of Flavopiridol in Relapsed or Refractory Mantle Cell Lymphoma (MCL) and Diffuse Large B-cell Lymphoma (DLBCL)
Phase II Study of Dose-Adjusted EPOCH +/-Rituximab in Adults with Untreated Burkitt Lymphoma, c-MYC+ Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma
Phase 1 Study of Ibrutinib and Immuno-chemotherapy using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma
Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated with a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs#xD;
A Random-Assignment Study of Hepatic Arterial Infusion of Melphalan with Venous Filtration via Peripheral Hepatic Perfusion (PHP) (Delcath System) Versus Best Alternative Care for Ocular and Cutaneous Melanoma Metastatic to the Liver
Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma
Tumor, Normal Tissue and Specimens from Patients Undergoing Evaluation or Surgical Resection of Solid Tumors
Retrospective Review of the Management of Malignant Peritoneal Mesothelioma
A Pilot Study of Imatinib Mesylate in Children and Adults with Sclerotic Skin Changes of Chronic Graft-Versus-Host Disease
Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas with Botulinum Toxin
A Phase 2 Study of Anakinra in Inflammatory Pustular Dermatoses: Evaluation of Therapeutic Efficacy and Validation of Pathogenic Mechanisms
Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells from the Original Transplant Donor to Patients with Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation
A Phase I Clinical Trial of T-cells Targeting B-cell Maturation Antigen for Previously Treated Multiple Myeloma
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Experimental Transplantation and Immunology Branch Studies
A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer
A Phase I Study of Dasatinib in Combination with Bevacizumab in Advanced Solid Tumors
Phase II Open Label Non-Randomized Single Agent Study of the SMAC (Second Mitochondrial-Derived Activator of Caspases)-Mimetic Birinapant (TL32711; NSC 756502) in Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer, Primary Peritoneal
Collection of Blood from Patients with Ovarian, Primary Peritoneal or Fallopian Tube Cancer
A Phase 1, Single Center, Dose-Escalation Study of SS1(dsFv)PE38 Administered Concurrently with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Epithelial Pleural Mesothelioma
Phase II Study of IMC-A12 in Patients with Mesothelioma who have been Previously Treated with Chemotherapy
A Pilot/ Phase II Study of Pentostatin Plus Cyclophosphamide Immune Depletion to Decrease Immunogenicity of SS1P in Patients with Mesothelioma, Lung Cancer or Pancreatic Cancer
An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose of the Antimesothelin Antibody Drug Conjugate BAY 94-9343 in Subjects with Advanced Solid Tumors#xD;
A Phase 1B Study to Evaluate the Safety and Induction of Immune Response of CRS 207 in Combination with Pemetrexed and Cisplatin as Front-line Therapy in Adults with Malignant Pleural Mesothelioma
Tissue Procurement and Natural History Study of Patients with Malignant Mesothelioma and Other Mesothelin Expressing Cancers
Long-Term Follow-Up of Subjects who have Participated in Aduro-sponsored Protocols
Phase IA/IB, Open-Label, Multicenter, Multiple Ascending Dose Study Followed by an Extension Phase to Evaluate the Safety, Tolerability, Pharmacokinetics and Activity of RO6927005, an anti-Mesothelin (MSLN) Recombinant Cytolytic Fusion Protein (cFP),
Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease#xD;
Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the
A Randomized Double-Blind Pilot Study of Topical Clobetasol 0.05% Oral rinse for Oral Chronic Graft-Versus-Host Disease
A Randomized Phase 2 Single-Center Study of Pomalidomide for Chronic GvHD
Collection of Saliva and/ or peripheral blood from Healthy Volunteers for Research
A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers
MR Image Guided Focal Therapy in Prostate Cancer
A Phase II Study of Neoadjuvant rFowlpox-PSA (L155)-TRICOM (Prostvac-F/TRICOM) in Combination with rVaccinia-PSA (L155)-TRICOM (Prostvac-V/TRICOM) in Men with Prostate Cancer Undergoing Treatment with Radical Prostatectomy
Prospective Procurement of Solid Tumor Tissue to Identify Novel Therapeutic Targets
Phase II Study in Patients with Metastatic Ocular Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Autologous Tumor-Infiltrating Lymphocytes with or without High Dose Aldesleukin
Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)
A Phase I Trial of 5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine in Advanced Malignancies
A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine with Tetrahydrouridine (FdCyd + THU)
Phase I Trial of Oral 5-Fluoro-2'-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors
Phase I Trial of 4'-thio-2'-deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors
A Phase II Study of BAY 43-9006 (Sorafenib) in Combination with Cetuximab (ErbituxTM) in EGFR Expressing Metastatic Colorectal Cancer (CRC)
Phase I Study of the Hsp90 Inhibitor, PU-H71, in Patients with Refractory Solid Tumors and Low-Grade Non-Hodgkinamp;#39;s Lymphoma
A Phase I and Pharmacokinetic Single-Agent Study of Romidepsin in Patients With Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors, and Varying Degrees of Liver Dysfunction
A Pilot Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity
Effects of Antimicrobial Treatments on the Microbiome in Healthy Volunteers and Patients with Atopic Dermatitis
Studies of Dermatologic Diseases-Biospecimen Acquisition Protocol
A Randomized Phase II Trial Combining Vaccine Therapy with PROSTVAC /TRICOM and Flutamide, vs. Flutamide Alone in Men with Androgen Insensitive, Non Metastatic (D0.5) Prostate Cancer
A Randomized Phase II Study of Tecemotide in Combination with Standard Androgen Deprivation Therapy and Radiation Therapy for Untreated, Intermediate and High Risk Prostate Cancer Patients
A Phase 2 Study of GI-6207 in Patients with Recurrent Medullary Thyroid Cancer
A Randomized Phase II Trial Combining Vaccine Therapy with PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men with Metastatic Castration Resistant Prostate Cancer
A Phase II Trial of Enzalutamide in Combination with PSA-TRICOM in Patients with Non-Metastatic Castration Sensitive Prostate Cancer
A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of VT-464 in Patients with Metastatic Castration Resistant Prostate Cancer Who Have Previously Been Treated with Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer
PET Imaging Of Renal Cell Carcinoma With 18F-VM4-037: A Phase II Pilot Study For Detection Of Disease And Correlation With VHL Mutation Status
Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)
A Phase II Trial of IPH2101 (anti-KIR) in Smoldering Multiple Myeloma (SMM)
Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Clinical and Correlative Phase II Study
A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination with mTOR inhibitor RAD001 (Everolimus) in Patients with Relapsed Multiple Myeloma or Lymphoma
Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: a Clinical and Correlative Study
Lenalidomide Maintenance Therapy in Multiple Myeloma: A Phase II Clinical and Biomarker Study
A phase I study with an expansion cohort of the PARP inhibitor AZD2281 (KU-0059436) combined with carboplatin in breast and ovarian cancer in BRCA 1/2 mutation carriers (familial breast and ovarian cancer) and sporadic triple negative breast cancer and
A Pharmacokinetic/Pharmacodynamic Study with a Phase I Run-In with a PARP Inhibitor (Olaparib) in Combination with Carboplatin for Refractory or Recurrent Women's Cancers
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Long-Term Storage of Specimens of Subjects Previously Enrolled in Multiple Studies of the Women's Cancers Clinic
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer
A Phase 2 Pilot Study of BMN 673 (Talazoparib), an Oral PARP Inhibitor, in Patients with Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer who have had prior PARP Inhibitor Treatment
Phase I/II Study of the Anti-programmed Death Ligand-1 Antibody MEDI4736 in Combination with Olaparib or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers
Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults with B Cell Malignancies#xD;
Pilot Study of Tocilizumab in Patients with Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - associated Multicentric Castleman Disease
A Phase I/II Study of an Antitumor Vaccination Using Alpha(1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients with Refractory or Recurrent Non-Small Cell Lung Cancer
A Pilot Study of Sirolimus (Rapamycin, Rapammune®) in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN
Prospective analysis of genotypes in adults undergoing therapy for lung cancer #xD; #xD;
Multicenter Phase II Study of IMC-A12 in Patients with Thymoma and Thymic Carcinoma who have been Previously Treated with Chemotherapy#xD; #xD;
A Phase 2, Open Label Trial of Dacomitinib (PF-00299804) in Selected Patients with Advanced Adenocarcinoma of the Lung
Phase 2, Open-Label Single Arm Study of the Efficacy and Safety of PF-02341066 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring a Translocation or Inversion Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus
A Phase 1/2 Study of PXD101 (Belinostat) in Combination with Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic Malignancies#xD; #xD;
Phase II Study of Oral PHA-848125AC in Patients with Thymic Carcinoma Previously Treated with Chemotherapy
Randomized Phase II Study of AZD6244 (mitogen-activated protein kinase inhibitor) MEK-Inhibitor with erlotinib in KRAS wild type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 with erlotinib in mutant KRAS Advanced
Phase II Study of Oral PHA-848125AC in Patients with Malignant Thymoma Previously Treated with Multiple Lines of Chemotherapy
A Phase II Study of Sunitinib in Patients with Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma with at Least One Prior Line of Platinum-Based Systemic Chemotherapy
A Phase 1, Open-label, Dose-escalation Study of SNX-5422 and Everolimus in Subjects with Neuroendocrine Tumors
A Phase 1 Study of AZD6244 in Combination with Cetuximab in Refractory Solid Tumors
A Multicenter Randomized Phase II Study of NPC-1C in Combination with Gemcitabine and nab-Paclitaxel versus Gemcitabine and nab-Paclitaxel Alone in Patients with Metastatic or Locally Advanced Pancreatic Cancer Previously Treated with FOLFIRINOX
A Pilot Study of Immune Checkpoint inhibition (Durvalumab with or without Tremelimumab) in Combination with Radiation Therapy in Patients with Unresectable Pancreatic Cancer
A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents and Young Adults with Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin's Lymphoma (NHL)
Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo® (Vincristine Sulfate Liposomes Injection) in Children and Adolescents with Refractory Cancer
A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation from Related or Matched Unrelated Donors in Pediatric Patients with Hematologic Malignancies
Defibrotide for Patients with Hepatic Veno-Occlusive Disease (VOD): A Treatment IND Study
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Phase I/II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients with Smoldering and Chronic Adult T-cell Leukemia (ATL)
Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator's Choice in Subjects with Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
A Phase I/Ib Study of Subcutaneous Recombinant Human NIZ985 [(hetIL-15) (IL15 / sIL-15Ra)] alone and in combination with PDR001 in Adults with Metastatic Cancers
An Open Label Phase I Study to Evaluate the Safety and Tolerability of a Modified Vaccinia Ankara (MVA) Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)
A Randomized, Double-Blind, Phase 2 Trial of GI-6301 (Yeast-Brachyury Vaccine) Versus Placebo in Combination with Standard of Care Definitive Radiotherapy in Locally Advanced, Unresectable, Chordoma.
Evaluation of the Natural History and Management of Pancreatic Lesions Associated with Von Hippel-Lindau
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
A Phase II Trial of Valproic Acid in Patients with Advanced Thyroid Cancers of Follicular Origin
Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer
Evaluation of Diagnostic and Prognostic Molecular Markers in Adrenal Neoplasm
A Phase I/II Trial of IL-13-PE in Patients with Treatment Refractory Malignancies with a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma
Evaluation of 68Gallium- DOTATATE PET/CT for Detecting Primary and Metastatic Neuroendocrine Tumors
Phase 1 Study of the Safety and Tolerability of ATR-101 in Adrenocortical Carcinoma
A Phase II Trial of Mutation-Targeted Therapy with Sunitinib or Everolimus in Patients with Advanced Low-or Intermediate Grade Neuroendocrine Tumors of the Gastrointestinal tract and Pancreas
Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial
A Phase I/II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma (HCC)
Acquisition of Blood and Tumor Tissue Samples from Patients with Gastrointestinal Cancer
A Phase II Study of TRC105 in Patients with Hepatocellular Carcinoma (HCC) Who Have Progressed on Sorafenib
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine (with Cyclophosphamide) Alone or Followed by CRS-207 in Adults with Metastatic Pancreatic Adenocarcinoma
A Phase I/II Study of ISIS 183750 in Combination with Irinotecan in Irinotecan-refractory Colorectal Cancer
A Pilot Study of Tremelimumab - A Monoclonal Antibody against CTLA-4 in combination with Trans-Arterial Catheter Chemoembolization (TACE), Radiofrequency Ablation (RFA) or Cryoablation in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract
A Pilot Study of AMP-224, a PD-1 Inhibitor, in Combination with Stereotactic Body Radiation Therapy (SBRT) in Patients with Metastatic Colorectal Cancer
Phase 2 Study of MK-3475 in Patients with Microsatellite Unstable (MSI) Tumors
A Pilot Study of AZD9150, a STAT3 Antisense Oligonucleotide in Malignant Ascites
A Phase II Study of TRC105 in Adults with Advanced/Metastatic Urothelial Carcinoma
A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients with Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors
NaF PET/CT Repeatability, Responsiveness, and Response Assessment in Patients with Metastatic Castrate-Resistant Prostate Cancer to Bone Treated with Either an Antimicrotubule Directed Agent or Androgen Receptor (AR)-Directed Therapy
A Phase II Study of Cabazitaxel in Patients with Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma
A Phase I/II Trial of Topotecan with VX970, an ATR Kinase Inhibitor in Small Cell Cancers
Pilot Study of Eovist® (Gadoxetate) Enhanced MRI for the Detection of Prostate Cancer
Evaluation of Ferumoxytol Enhanced MRI for the Detection of Lymph Node Metastases in Genitourinary (Prostate, Bladder and Kidney) Cancers
Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies
Phase I/II Trial of PLX3397 in Children and Young Adults with Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
Randomized Controlled Trial of Total Thyroidectomy with and without Prophylactic Central Neck Lymph Node Dissection in Patients with Low-risk Papillary Thyroid Cancer
A Pilot Study of 18F-DCFBC PET/CT in Prostate Cancer
The Melanoma Disease Management Program Psychosocial/ Behavioral/ Epidemiology/ Prevention Studies
Biomarkers and Histopathology of Merkel cell carcinoma
A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of MSB0010718C in Subjects with Merkel Cell Carcinoma
A Phase 1, Dose Escalation Study of MGAH22 (Fc-optimized Chimeric Anti-HER2 Monoclonal Antibody) in Patients with Refractory HER2 Positive Breast Cancer and Patients with Other HER2 Positive Carcinomas for Whom No Standard Therapy Is Available
Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
A Pilot Study of Inpatient Hospice with Procurement of Tissue on Expiration in Thoracic Malignancies
Tissue Procurement and Natural History Study of Patients with Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) given in combination with PANVAC versus BCG given alone in Adults with High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) who failed at least 1
Care of the Urothelial Cancer Patient and Prospective Collection of Biospecimens from Healthy Volunteers and Urothelial Cancer Patients
Evaluation of the Natural History of Patients with Tumors of the Central Nervous System
Expanded Access (Compassionate Use) Treatment Protocol with Rindopepimut (CDX-110)
Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients with Newly Diagnosed Glioblastoma
A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes (TIL) Derived from Patients with Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative Regimen
Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing Human Thyroglobulin to Patients with Thyroglobulin Expressing Thyroid Cancer
A Phase I Study of Ipilimumab (Anti-CTLA4) in Children, Adolescents, and Young Adults with Treatment Refractory Cancer
A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Cross-Over, Phase II.5 Study of Saracatinib (AZD0530), a Selective Src Kinase Inhibitor, in Patients with Recurrent Osteosarcoma Localized to the Lung
An Open-Label, Multicenter, Single-Arm, Phase I Dose-Escalation with Efficacy Tail Extension Study of RO5185426 in Pediatric Patients with Surgically Incurable and Unresectable Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Care of the Adult Oncology Patient, CCR, NCI
A Phase II Trial of Docetaxel, Thalidomide, Prednisone, and Bevacizumab in Patients with Androgen-Independent Prostate Cancer
A Phase 2 trial of Bevacizumab, Lenalidomide, Docetaxel and Prednisone(ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer
A Phase II Multicenter Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer
A Phase I and Randomized Phase II Multicenter Study of Cabozantinib (XL184) plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer
Neoadjuvant Androgen Deprivation and Enzalutamide: Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
Exceptional Responders Pilot Study: Molecular Profiling of Tumors from Cancer Patients who are Exceptional Responders
A Pilot Study of Vaccination with Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma
A Targeted Phase I/II trial of ZD6474 (Vandetanib CAPRELSA) Plus the Proteasome Inhibitor, Bortezomib (Velcade®), in Adults with Solid Tumors with a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
A Phase I/II Trial of Crolibulin (EPC2407) plus Cisplatin in Adults with Solid Tumors with a Focus on Anaplastic Thyroid Cancer (ATC)
Phase II Study of Axitinib (AG-013736) with Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma
A Randomized Trial of Filgrastim-SD/01 vs Filgrastim in Newly Diagnosed Children and Young Adults with Sarcomas Treated with Dose-Intensive Chemotherapy
Eligibility Screening and Tissue Procurement for the National Cancer Institute (NCI), Pediatric Oncology Branch (POB) Clinical Research Protocols
A Phase I Trial of Monoclonal Antibody HGS-ETR2 (Lexatumumab) With or Without Interferon Gamma in Patients with Refractory Pediatric Solid Tumors
Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research-Network (CCRN) Childrenamp;#39;s Oncology Group
A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T cells in HLA-A2+ Patients with Synovial Sarcoma
A Phase I Trial of T Cells Expressing an anti-GD2 Chimeric Antigen Receptor in Children and Young Adults with GD2+ Solid Tumors
Follow-Up Evaluation for Gene-Therapy Related Delayed Adverse Events after Participation in Pediatric Oncology Branch Clinical Trials
Phase I/II Study of Nivolumab (IND#124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
A pilot study of autologous T-cell transplantation with vaccine driven expansion of anti-tumor effectors after cytoreductive therapy in metastatic pediatric sarcomas
Treatment of Children with Cancer
A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for CD25 Positive Hairy Cell Leukemia
A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patients with Relapsed or Refractory Hairy Cell Leukemia (HCL)
Request to Conduct Research for Same Use of Stored Human Samples, Specimens, or Data Collected in a Terminated NCI-IRB Protocol. Protocol Numbers of Terminated Protocols: 96C0064; 99C0014; 98C0078; 94C0172; 03C0243; 01C0011; 09C0076; 04C0121; 04C0142;
Randomized Trial of Cladribine (CdA) with Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease
Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
Randomized Phase II Trial of Rituximab with Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Collection of Human Samples to Study Hairy Cell and Other Leukemias and to Develop Recombinant Immunotoxins for Cancer Treatment
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia
A Phase II, Open-label Study in Patients with BRAF V600E-Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib
Hematologic Malignancy Biology Study
A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies#xD;
Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults with Recurrent or Refractory CD22-expressing B Cell Malignancies
Characterization of High-Risk Breast Duct Epithelium by Cytology, Breast Duct Endoscopy, and cDNA Gene Expression Profile
Proteomic-based Profiling of Lymphomas: Chromatin proteomics; composition and modification of histone and non-histone chromosomal proteins
Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome
Low Intensity Allogeneic Hematopoietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells
Rapamycin-Resistant T Cell Therapy of Multiple Myeloma: Relapse Prevention and Relapse Therapy
Mobilization and Collection of Autologous Hematopoietic Progenitor Cell (HPC) for Transplantation (AHCT) for Plasma Cell Myeloma(PCM)
Expression of the Genome in Lymphoid Malignancies
The Acquisition of Blood and Skin Samples from Patient Volunteers to Support Research Activities on Dermatologic and Other Diseases
Evaluation and Treatment of Subjects with Dermatologic Diseases
Pharmacological Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Retrospective Analysis of Drug Disposition and Response-Related Genotypes in Cancer Patients and Correlation with Pharmacokinetics and Pharmacodynamics Data
Collection of Blood from Patients with Prostate Cancer
Collection of Tissue Blocks or Slides from Patients with Cancer
Collection of Blood from Patients with Cancer for Analysis of Genetic Differences in Drug Disposition
Long-Term Retention of Prospectively Obtained Biospecimens
Collection of Pharmacokinetic Samples from Patients with Unanticipated Response or Toxicity
Biospecimen Acquisition from Human Subjects
An Open Label Pilot Study to Evaluate the Safety and Tolerability of PANVAC(TM)-V (Vaccinia) and PANVAC (TM)-F (Fowlpox) in Combination with Sargramostim in Adults with Metastatic Carcinoma
Follow-Up Study of Subjects Previously Enrolled in Immunotherapy Studies Utilizing Gene Transfer or other immunotherapeutic agents
A Randomized Pilot Phase II Study of Docetaxel Alone or in Combination With PANVAC[TM]-V (vaccinia) and PANVAC[TM]-F (fowlpox) in Adults with Metastatic Breast Cancer
First In-Human Phase I Trial of NHS-IL12 in Patients with Metastatic Solid Tumors
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ± GM-CSF in Men with Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer
An Open Label Phase I Study to Evaluate the Safety and Tolerability of GI-6301 Vaccine Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (yeast) Genetically Modified to Express Brachyury Protein in Adults with Solid Tumors
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of avelumab (MSB0010718C), a monoclonal anti-PD-L1 antibody, in subjects with metastatic or locally advanced
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer or Normal Volunteers
Phase II Trial of Depsipeptide (NSC 630176) in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-cell Lymphoma
A Pilot Study of Tc-94m Sestamibi PET MDR Imaging
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
A Phase 1, Dose-escalation Study of the Safety, Tolerability and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies
A Phase I Study of Belinostat in Combination with Cisplatin and Etoposide in Adults with a Focus on Small Cell Lung Cancer and other Cancers of Neuroendocrine Origin
A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination with Trastuzumab in Breast Cancer Subjects with Brain Metastases
The Birt Hogg Dube' Syndrome: Identification of the Disease Gene, and Characterization of the Predisposition to Renal Cancer
Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene, and Characterization of the Predisposition to Renal Cancer
A Phase 2 Study of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Von Hippel Lindau Disease and Renal Tumors
A Phase 2 Study of ZD6474 (vandetanib) in Patients with von Hippel Lindau Disease and Renal Tumors
Clinical Manifestations and Molecular Bases of Heritable Urologic Malignant Disorders
Collection of Serum and Tissue Samples from Patients with Biopsy-Proved or Suspected Malignant Diseases
A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area
A Collaborative Case-Control Study of Genetic Associations, Biomarker Discovery and Risk Factors for Liver Cancer in Thailand
Multi-institutional Prospective Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans following Allogeneic or Autologous Stem Cell Transplantation in Children and Adults#xD;
Autologous and Related Allogeneic Hematopoietic Stem Cell Transplant and Cellular Therapies Data Submission to the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow Donor Program (NMDP)
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
Study of the Biology and Natural History of Disease Outcomes in Patients Treated with Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies
Multi-institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution following Allogeneic Bone Marrow Transplantation in Post-pubertal Children and Adults with Molecular Imaging Evaluation
A Multicenter Phase II Study of Enhancement of Immune Reconstitution and Vaccine Responses with Administration of Glyco-recombinant Human IL-7 in Older Subjects Following Chemotherapy
Targeted Therapy of Bronchiolitis Obliterans Syndrome (BOS)
Pilot Study of Idiotype Vaccine and EPOCH-Rituximab Chemotherapy in Untreated Mantle Cell Lymphoma
Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas
Combination Antibody Therapy with Apolizumab [1D10] and Rituximab [CD20] in Relapsed Lymphoma and CLL
Phase 2 Trial of Alemtuzumab and Dose-Adjusted EPOCH In Chemotherapy Naive Aggressive T and NK-Cell Lymphomas
Phase II Study of UCN-01 in Relapsed or Refractory Systemic Anaplastic Large Cell and Mature T-Cell Lymphomas
Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib Induction Followed by Bortezomib Maintenance versus Observation in Untreated Mantle Cell Lymphoma with Microarray Profiling and Proteomics
Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated de Novo Diffuse Large B-Cell Lymphomas
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Lymphoid Malignancies
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in T and NK-cell Lymphomas
Phase II trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in relapsed or refractory Diffuse Large B-Cell and Hodgkin Lymphomas
A RANDOMIZED PHASE II STUDY OF RITUXIMAB WITH ABVD VERSUS STANDARD ABVD FOR SUBJECTS WITH ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA WITH POOR RISK FEATURES (IPS SCORE gt; 2)
A Phase 2 Study of AZD6244 in Multiple Myeloma
Phase 1 Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects with Relapsed or Refractory de novo Diffuse Large B-cell Lymphoma
Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol
A Phase 2 Multicenter, Investigator Initiated Study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-cell and Peripheral T-cell Non-Hodgkin Lymphoma
A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly
A Multicenter Study of Ibrutinib and Lenalidomide in Combination with DA-EPOCH-R in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children with Previously Untreated Patients with Aggressive Non-Hodgkin's Lymphoma
Treatment and Natural History Study of Lymphomatoid Granulomatosis
EPOCH Chemotherapy Plus Rituximab for Previously Treated Patients with AIDS-Associated Lymphoma
Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis
Phase 2 Study of the C-Met RTK Inhibitor Foretinib (formerly GSK 1363089) in Subjects with Papillary Renal Cell Carcinoma (PRC).
A Phase II Study of Bevacizumab and Erlotinib in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
A pilot study of F-18 paclitaxel (FPAC) PET for evaluating drug delivery to solid tumors
A pilot study of F-18 sodium fluoride PET/CT for metastatic burden quantification in prostate cancer
Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine
Acceptance and Commitment Therapy for Adolescents and Adults with Neurofibromatosis Type 1 and Chronic Pain: A Pilot Study
Validation of the English Version of the Pain Interference Index and the Pain Rating Scale in Children, Adolescents, and Young Adults with Chronic Illness and Their Parents
Effects of an Internet Support Group for Parents of a Child with Neurofibromatosis Type 1
Acceptance and Commitment Training for Adolescents and Adults with Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain: A Phase III Clinical Trial
Analysis of Stored Data Collected from Individuals Administered Neurobehavioral Assessments on IRB-approved Protocols
A Randomized Controlled Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated with Cranial Radiation for Brain Tumors
The Impact of Ras/MAPK Signaling Pathway-targeted Therapies on Neurocognitive Functioning in Individuals with NF1
An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin
Evaluation of Local Response of Prostate Cancer to Irradiation Using Multiparametric MRI and MR-Guided Biopsies
A Phase II Protocol for Subjects with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radio-sensitizing Chemotherapy following a Thorough Transurethral Surgical Re-Staging
A Phase I Study of Image Guided Dose Escalation with Intensity Modulated Radiation Therapy (IMRT) to Histologically Confirmed Regions of Prostate Cancer
A Pilot Study of Image Guided Prostate and Pelvic Nodal Irradiation with Intensity Modulated Radiation Therapy (IMRT) in Prostate Cancer
A Pilot Study of High Dose Rate Brachytherapy in The Radiation Oncology Branch#xD; #xD;
Evaluation of Late Effects and Natural History of Disease in Patients Treated with Radiotherapy
Evaluation for NCI Radiation Oncology Branch Clinical Research Protocols
Collection of Peripheral Blood and/or Urine from Patients Undergoing Radiation Therapy
A Phase II Study of MR-Guided High Dose Rate Brachytherapy Boosts for Prostate Cancer
Amifostine as a Rectal Protector During External Beam Radiotherapy for Prostate Cancer: A Phase II Study
Trans-Rectal Placement of Prostatic Fiducial Markers Under MR-Guidance in Patients Receiving External Beam Radiotherapy for Prostate Cancer: A Pilot Study
The Natural History of Childhood Malignancies Treated with Radiation Therapy
A Prospective Histopathologic Study of Dynamic Contrast Enhanced MRI for Prostate Cancer Delineation and Characterization with the APT-MRI System
Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence
A Phase II Clinical Trial of the Histone Deacetylase Inhibitor Valproic Acid in Combination with Temodar and Radiation Therapy in Patients with High Grade Gliomas: A Multi-Institutional Trial
A Pilot Study to Evaluate Neuropsychological Outcome Measures and their Relationship with Prognosis in Patients Receiving Radiation Therapy for Brain Metastases
The Treatment of Stage I and II Carcinoma of the Breast with Mastectomy and Axillary Dissection vs. Excisional Biopsy Axillary Dissection, and Definitive Irradiation
Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for Patients with GATA2 Mutations
Related and Unrelated Donor Hematopoietic Stem Cell Transplant for DOCK8 Deficiency
Apheresis and CD34+ Selection of Mobilized Peripheral Blood CD34+ Cells from Patients with DOCK8 Deficiency, LAD-1, and GATA2 Deficiency#xD;
Allogeneic Hematopoietic Stem Cell Transplant for Patients with Mutations in GATA2 or the MonoMAC syndrome
Natural History of Plexiform Neurofibromas in Neurofibromatosis Type I
Phase I Trial and Pharmacokinetic Study of Tariquidar (XR9576), a P-Glycoprotein Inhibitor, in Combination with Doxorubicin, Vinorelbine or Docetaxel in Pediatric Patients with Refractory Solid Tumors Including Brain Tumors
Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772 IND# 69896) in Children with Refractory Solid Tumors or Refractory Leukemias
Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents with Hereditary Medullary Thyroid Carcinoma
Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults with Neurofibromatosis Type 1
A Phase II Trial of Peginterferon alfa-2b (PEG-Intron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas
Phase 2 Study of Bevacizumab in Children and Adults with Neurofibromatosis Type 2 and Symptomatic Vestibular Schwannoma
A Phase I/II Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; Hydrogen Sulfate in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults with Relapsed / Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Phase I/II Trial of Mithramycin in Children and Adults with Refractory Extracranial Solid Tumors (Phase I) or Ewing Sarcoma and EWS-FLI1 Fusion Transcript (Phase II)
SARC016: Phase 2 Study of the mTOR Inhibitor Everolimus in Combination with Bevacizumab in Patients with Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Longitudinal Assessment and Natural History Study of Children and Adults with MEN2A or MEN2B with or without Medullary Thyroid Carcinoma
Phase 1 Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients with Relapsed or Refractory Solid Tumors
A Phase I Study of XL184 (Cabozantinib, IND# 116059) in Children and Adolescents with Recurrent or Refractory Solid Tumors, Including CNS Tumors
Phase II Trial of Vandetanib (ZD6474, Caprelsa(R)) in Children and Adults with Wild-Type Gastrointestinal Stromal Tumors
A Phase I/II Trial of Ganetespib in Combination with the mTOR Inhibitor Sirolimus for Patients with Recurrent or Refractory Sarcomas including Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Clinical, Histopathologic, and Genomic Analysis
A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects with Neurofibromatosis Type 1 in Children and Adults
A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults with NF1- Associated Morbid Plexiform Neurofibromas
A Feasibility Trial using Molecular-Guided Therapy for the Treatment of Patients with Refractory or Recurrent Neuroblastoma
A Phase II Study of Pegylated Interferon Alfa-2b (Peg-Intron) in Children with Diffuse Pontine Gliomas
A Comparative Study of Pediatric CNS Tumor Activity as Assessed by 18F-FDG PET Imaging and Proton Magnetic Resonance Spectroscopic Imaging (1H-MRSI)
A Phase II Trial of Tamoxifen and Bortezomib in Patients with Recurrent High-Grade Gliomas
An Exploratory Study of Biologic and Pathophysiologic Effects of Radiation Therapy in Pediatric Patients with Central Nervous System Tumors
A PHASE I TRIAL OF ENZASTAURIN (LY317615) IN COMBINATION WITH CARBOPLATIN IN ADULTS WITH RECURRENT GLIOMAS
A Phase II Trial of Enzastaurin (LY317615) in Combination with Bevacizumab in Adults with Recurrent Malignant Gliomas
A PHASE 2 TRIAL OF TANDUTINIB IN COMBINATION WITH BEVACIZUMAB FOR PATIENTS WITH RECURRENT HIGH-GRADE GLIOMAS
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination with Carboplatin versus Carboplatin Alone Followed by Vandetanib Alone in Adults with Recurrent High-Grade Gliomas
A Phase I Trial of Lenalidomide and Radiotherapy in Children with Diffuse Intrinsic Pontine Gliomas and High-grade Gliomas
PHASE I TRIAL OF AZD8055, AN ORAL MTOR KINASE INHIBITOR, FOR ADULTS WITH RECURRENT GLIOMAS
A Phase 1 and Phase II and Retreatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
A RANDOMIZED PHASE I/II STUDY OF ABT-888 IN COMBINATION WITH TEMOZOLOMIDE IN RECURRENT (TEMOZOLOMIDE RESISTANT) GLIOBLASTOMA
PBTC-033 A Phase I/II Study of ABT-888, an Oral Poly (ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children with Newly Diagnosed Diffuse Pontine Gliomas (DIPG)
A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients with Primary and Metastatic Brain Tumors
1H-Nuclear Magnetic Resonance Spectroscopic Imaging of the Brain in Patients Who Receive Neurotoxic Therapy
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion with or without Concurrent Celecoxib in Subjects with Pulmonary and Pleural Malignancies
Prospective Evaluation of Genetic and Epigenetic Alterations in Patients with Thoracic Malignancies
Allogeneic Tumor Cell Vaccine with Metronomic Oral Cyclophosphamide and Celecoxib as Adjuvant Therapy for Lung and Esophageal Cancers, Thymic Neoplasms, Thoracic Sarcomas, and Malignant Pleural Mesotheliomas
Adjuvant Allogeneic Tumor Cell Vaccine with Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to Lungs, Pleura, or Mediastinum
Epigenetically-Modified Autologous Tumor Cell Vaccines and ISCOMATRIX(TM) Adjuvant with Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to
Phase I/ II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax) in the Therapy of Tac-Expressing Adult T-Cell Leukemia
A Phase I Investigation of IL-12/Pulse IL-2 in Adults with Advanced Solid Tumors
Phase II Study of the Efficacy and Toxicity of CAMPATH-1H in the Therapy of Adult T-Cell Leukemia
Phase I Trial of Medi-507 in CD2-Positive Lymphoproliferative Disease
A Phase I Open-Label Single-Dose Study of Humanized MIK-BETA-1 Monoclonal Antibody Directed Toward the IL-2R/IL-15R{beta} Subunit (CD122) in T Cell Large Granular Lymphocytic Leukemia
A Phase II Study of the Efficacy and Toxicity of ONTAK (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
A Phase I Study of Intravenous Recombinant Human IL-15(rhIL-15) in Adults with Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer
A Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Head and Neck Cancer
Phase I Study of the Humanized Mik-Beta-1 Monoclonal Antibody Directed Toward IL-2/IL-15R beta (CD122) that Blocks IL-15 Action in Patients with Refractory Celiac Disease
A Phase I/II Study of Tac-Expressing Malignancies (Other than ATL) with Yttrium-90 (90Y)-Radiolabeled Humanized Anti-Tac and Calcium-DTPA
Collection of Blood, Bone Marrow and Tissue samples for the Investigation of the Human Immune Response, Lymphoma Biology and HTLV-1 Infection
Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophelia Cohort (HGDS-3)
Discovery of Genetic Variants Contributing to the Incidence or Course of CMV Disease in AIDS Patients
BRCA1 and BRCA2 Mutations and Triple Negative Disease in Hispanic/Latino Breast Cancer Subjects
Cell Harvest and Preparation for Surgery Branch Adoptive Cell Therapy Protocols
Blood and Tissue Analysis in Surgery Branch NCI from Stored Samples
Phase II Study of Metastatic Cancer that Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes
An Assessment of the Safety and Feasibility of Administering T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients with B-Cell Lymphoma
Follow up Protocol for Subjects Previously Enrolled in NCI Surgery Branch Studies
A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab
Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes#xD;
A Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor-Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction with
A Pilot Study of the Administration of Young Tumor Infiltrating Lymphocytes following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma
A Phase I/II Study of the Safety and Feasibility of Administering T-Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients with Malignant Gliomas Expressing EGFRvIII#xD;
A Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-Mesothelin Gene Engineered Lymphocytes#xD;
A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma
A Phase II Study of Lymphodepletion followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers
A Phase II Study of Metastatic Cancer that Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes
A Phase II Study for Metastatic Melanoma Using High-Dose Chemotherapy Preparative Regimen Followed by Cell Transfer Therapy Using Tumor-Infiltrating Lymphocytes Plus IL-2 with the Administration of Pembrolizumab in the Retreatment Arm
A Phase I/II Study of the Treatment of Metastatic Cancer that Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of HLA-DP0401/0402 Restricted Anti-MAGE-A3 TCR-Gene Engineered Lymphocytes and Aldesleukin
Phase II Study of CD62L+-derived T lymphocytes transduced with a T Cell Receptor Recognizing the NY-ESO-1 Antigen and Aldesleukin Following Lymphodepletion in Patients with NY-ESO-1 Expressing Melanoma
A Phase II Study of Cell Transfer Therapy for Metastatic Melanoma Using 41BB Selected Tumor Infiltrating Lymphocytes Plus IL-2 Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen
Phase I/II Study of the Treatment of Metastatic Cancer that Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3 HLA-A*01 Restricted TCR-Gene Engineered Lymphocytes and Aldesleukin
A Phase I Trial for the Evaluation of the In Vivo Persistence of Adoptively-transferred Tumor-Infiltrating Lymphocytes Cultured with a Pharmacologic Inhibitor of AKT in Patients with Metastatic Melanoma
Evaluation for NCI Surgery Branch Clinical Research Protocols
Biomarker Analysis of Lymphoma and Lymphoproliferative Diseases
DNA Methylation in Gray Zone Lymphoma compared to Hodgkin Lymphoma, Primary Mediastinal Large Cell Lymphoma and Diffuse Large B-Cell Lymphoma
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with HIV Infection, KSHV Infection, Viral-related Pre-malignant Lesions, and/or Cancer
Protocol to Assess Vascularity in Kaposi's Sarcoma Lesions Utilizing Non-invasive Tumor Imaging
Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease with Laboratory and Clinical Correlates of Disease Activity
AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate with Rituximab, Leucovorin Rescue and Highly Active Antiretroviral Therapy
Phase I and Pharmacokinetic Study of BAY 43-9006 (Sorafenib) in Patients with Kaposiamp;#39;s Sarcoma
Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab Followed by Bevacizumab Monotherapy in Adults with Advanced Kaposi's Sarcoma
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS) Incorporating Pilot Evaluation of KSHV Targeted Therapies
A Phase I/II Study of the Safety, Pharmacokinetics and Efficacy of Pomalidomide (CC-4047) in the Treatment of Kaposi Sarcoma in Individuals With or Without HIV
Cancer Risk in Xeroderma Pigmentosum Heterozygotes
Examination of Clinical and Laboratory Abnormalities in Patients with Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy
A Phase 0 Trial of [111]Indium CHX-A DTPA Trastuzumab Imaging in Cancer
Pilot Study of Educational Interventions in Pediatric Hematopoietic Stem Cell Donors to Increase Knowledge of Donation and Transplantation Procedures
Understanding the Psychosocial Needs of Parents Who Have Lost a Child to Cancer
Understanding the Perceived Influence of Childhood Cancer on the Parents' Marital/partner Relationship: A Descriptive Study
An Exploratory Study of Voicing My CHOiCES as a Tool for Advanced Care Planning in Young Adults with Cancer and Other Life Threatening Illnesses
A Group Wide Biology and Banking Study for Phase II Studies of R1507
Phase 1 Study of a Combination of the PARP inhibitor, Niraparib and Temozolomide in Patients with Previously Treated, incurable Ewing's Sarcoma
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents and Young Adults
A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/neu ECTM in Adults with Tumors with 1-3+ HER2/neu Expression
A Randomized, Placebo-Controlled Phase II Study of Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men with Stage D0 Prostate Cancer
A Pilot Study of Long Term TARP Vaccination Using A Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccine in Previously Vaccinated Men on NCI 09-C-0139.